FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1917372364> ?p ?o ?g. }

• W1917372364 abstract "Background Hepatorenal syndrome is defined as severe renal failure occurring in people with cirrhosis and ascites. Systematic reviews of randomised clinical trials found that, compared with placebo, terlipressin may reduce mortality and improve renal function in people with hepatorenal syndrome, but we need current evidence from systematic reviews on the benefits and harms of terlipressin versus other vasoactive drugs. Objectives To evaluate the beneficial and harmful effects of terlipressin versus other vasoactive drugs for people with hepatorenal syndrome. Search methods We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, and Science Citation Index Expanded; conducted manual searches of references in relevant literature; and wrote to experts and pharmaceutical companies (date of last search November 2016). Selection criteria Randomised clinical trials comparing terlipressin versus any other type of vasoactive drugs for hepatorenal syndrome. We allowed albumin and other cointerventions if provided equally in the comparison groups. Data collection and analysis Three authors independently extracted data. The primary outcomes were mortality, hepatorenal syndrome (persistent hepatorenal syndrome despite treatment), and serious adverse events. We conducted meta‐analyses and present the results as risk ratios (RR) with 95% confidence intervals (CI). We performed sensitivity, subgroup, and Trial Sequential Analyses and evaluated bias control based on the Cochrane Hepato‐Biliary Group domains. Main results We included 10 randomised clinical trials with 474 participants. The trials compared terlipressin versus noradrenaline (seven trials), octreotide (one trial), midodrine and octreotide (one trial), or dopamine (one trial). All participants in both groups received albumin as cointervention. We classified two trials at low risk of bias and eight trials at high risk of bias in the assessment of mortality and all trials at high risk of bias for remaining outcomes. In five trials, investigators specifically stated that they did not receive funding from for‐profit organisations. We had no information about the funding source from the remaining five trials. Terlipressin was not superior or inferior compared with other vasoactive drugs in regard to mortality when including the two trials with a low risk of bias (RR 0.92, 95% CI 0.63 to 1.36; 94 participants, very low quality evidence) or when including all 10 trials (RR 0.96, 95% CI 0.88 to 1.06; 474 participants; I² = 0%; very low quality evidence). One meta‐analysis including nine trials suggested a beneficial effect of terlipressin on hepatorenal syndrome (RR 0.79, 95% CI 0.63 to 0.99; 394 participants; I² = 26%; very low quality evidence). Due to the high mortality of hepatorenal syndrome, the registration of other serious adverse events is uncertain, but comparing terlipressin and other vasoactive drugs we found no significant difference (RR 0.96, 95% CI 0.88 to 1.06; 474 participants; I² = 0%; very low quality evidence). Several trials did not report systematically of adverse events, but terlipressin seemed to increase the risks of diarrhoea or abdominal pain, or both (RR 3.50, 95% CI 1.19 to 10.27; 221 participants; 5 trials, I² = 0%). However, Trial Sequential Analyses found insufficient evidence to support or refute any differences between interventions for all outcomes. Considering reversal of hepatorenal syndrome, subgroup analyses on the type of other vasoactive drugs found that terlipressin was superior compared with midodrine and octreotide (RR 0.47, 95% CI 0.30 to 0.72) or octreotide alone (RR 0.56, 95% CI 0.33 to 0.96), but each subgroup only included one small trial. None of the remaining subgroup or sensitivity analyses found differences between terlipressin and other vasoactive drugs. We downgraded the evidence to very low quality because of the high risk of bias, imprecision, and the results of the Trial Sequential Analyses. Authors' conclusions This review found insufficient evidence to support or refute beneficial or harmful effects of terlipressin and albumin versus other vasoactive drugs and albumin. Additional research is needed to evaluate if clinically meaningful differences exist between interventions." @default.
• W1917372364 created "2016-06-24" @default.
• W1917372364 creator A5032309738 @default.
• W1917372364 creator A5035755869 @default.
• W1917372364 creator A5036506783 @default.
• W1917372364 creator A5037909839 @default.
• W1917372364 creator A5046406176 @default.
• W1917372364 creator A5075627655 @default.
• W1917372364 creator A5085229958 @default.
• W1917372364 date "2017-09-27" @default.
• W1917372364 modified "2023-10-14" @default.
• W1917372364 title "Terlipressin versus other vasoactive drugs for hepatorenal syndrome" @default.
• W1917372364 cites W1228830179 @default.
• W1917372364 cites W1269360376 @default.
• W1917372364 cites W1715347104 @default.
• W1917372364 cites W1899691766 @default.
• W1917372364 cites W1964489041 @default.
• W1917372364 cites W1964502734 @default.
• W1917372364 cites W1967300023 @default.
• W1917372364 cites W1967589221 @default.
• W1917372364 cites W1971441597 @default.
• W1917372364 cites W1971969855 @default.
• W1917372364 cites W1972241537 @default.
• W1917372364 cites W1982355832 @default.
• W1917372364 cites W1998341790 @default.
• W1917372364 cites W2002430590 @default.
• W1917372364 cites W2011199481 @default.
• W1917372364 cites W2018940564 @default.
• W1917372364 cites W2032310250 @default.
• W1917372364 cites W2036652612 @default.
• W1917372364 cites W2039418122 @default.
• W1917372364 cites W2043785558 @default.
• W1917372364 cites W2045376161 @default.
• W1917372364 cites W2045620941 @default.
• W1917372364 cites W2051278614 @default.
• W1917372364 cites W2064739831 @default.
• W1917372364 cites W2074466817 @default.
• W1917372364 cites W2081963999 @default.
• W1917372364 cites W2094598763 @default.
• W1917372364 cites W2097744101 @default.
• W1917372364 cites W2099765590 @default.
• W1917372364 cites W2103472550 @default.
• W1917372364 cites W2104802633 @default.
• W1917372364 cites W2108153775 @default.
• W1917372364 cites W2110616090 @default.
• W1917372364 cites W2120179295 @default.
• W1917372364 cites W2123173269 @default.
• W1917372364 cites W2131903288 @default.
• W1917372364 cites W2135617792 @default.
• W1917372364 cites W2148609006 @default.
• W1917372364 cites W2160795579 @default.
• W1917372364 cites W2164601307 @default.
• W1917372364 cites W2178421940 @default.
• W1917372364 cites W2214600008 @default.
• W1917372364 cites W2259239042 @default.
• W1917372364 cites W2268481349 @default.
• W1917372364 cites W2282617728 @default.
• W1917372364 cites W2317935894 @default.
• W1917372364 cites W2322673970 @default.
• W1917372364 cites W2417098694 @default.
• W1917372364 cites W2522950990 @default.
• W1917372364 cites W2557658892 @default.
• W1917372364 cites W2568876760 @default.
• W1917372364 cites W2593363470 @default.
• W1917372364 cites W2613483874 @default.
• W1917372364 cites W2626626916 @default.
• W1917372364 cites W4237367369 @default.
• W1917372364 cites W4239126660 @default.
• W1917372364 cites W4255387568 @default.
• W1917372364 cites W4300173072 @default.
• W1917372364 cites W80909407 @default.
• W1917372364 cites W2541299098 @default.
• W1917372364 doi "https://doi.org/10.1002/14651858.cd011532.pub2" @default.
• W1917372364 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6483765" @default.
• W1917372364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28953318" @default.
• W1917372364 hasPublicationYear "2017" @default.
• W1917372364 type Work @default.
• W1917372364 sameAs 1917372364 @default.
• W1917372364 citedByCount "31" @default.
• W1917372364 countsByYear W19173723642017 @default.
• W1917372364 countsByYear W19173723642018 @default.
• W1917372364 countsByYear W19173723642019 @default.
• W1917372364 countsByYear W19173723642020 @default.
• W1917372364 countsByYear W19173723642021 @default.
• W1917372364 countsByYear W19173723642022 @default.
• W1917372364 countsByYear W19173723642023 @default.
• W1917372364 crossrefType "journal-article" @default.
• W1917372364 hasAuthorship W1917372364A5032309738 @default.
• W1917372364 hasAuthorship W1917372364A5035755869 @default.
• W1917372364 hasAuthorship W1917372364A5036506783 @default.
• W1917372364 hasAuthorship W1917372364A5037909839 @default.
• W1917372364 hasAuthorship W1917372364A5046406176 @default.
• W1917372364 hasAuthorship W1917372364A5075627655 @default.
• W1917372364 hasAuthorship W1917372364A5085229958 @default.
• W1917372364 hasBestOaLocation W19173723642 @default.
• W1917372364 hasConcept C126322002 @default.
• W1917372364 hasConcept C142724271 @default.
• W1917372364 hasConcept C168563851 @default.
• W1917372364 hasConcept C177713679 @default.
• W1917372364 hasConcept C204787440 @default.

• next